BR112013000877A2 - processo para a preparação de um ácido bifenil-2-il carbâmico - Google Patents

processo para a preparação de um ácido bifenil-2-il carbâmico

Info

Publication number
BR112013000877A2
BR112013000877A2 BR112013000877A BR112013000877A BR112013000877A2 BR 112013000877 A2 BR112013000877 A2 BR 112013000877A2 BR 112013000877 A BR112013000877 A BR 112013000877A BR 112013000877 A BR112013000877 A BR 112013000877A BR 112013000877 A2 BR112013000877 A2 BR 112013000877A2
Authority
BR
Brazil
Prior art keywords
biphenyl
preparation
carbamic acid
ester
preparing
Prior art date
Application number
BR112013000877A
Other languages
English (en)
Other versions
BR112013000877B1 (pt
Inventor
Pierre-Jean Colson
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BR112013000877A2 publication Critical patent/BR112013000877A2/pt
Publication of BR112013000877B1 publication Critical patent/BR112013000877B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

processo para a preparação de um ácido bifenil-2-il carbâmico. a invenção proporciona um processo de preparação de um intermediário útil na síntese de éster de 1-(2-{[4-(4-carbamoilpiperidina-1-il metil) benzoil] metilamino}etil)piperidin-4-ila de ácido bifenil-2-il carbâmico, e um processo de preparação de uma base livre cristalina do éster.
BR112013000877-6A 2010-07-13 2011-06-30 processo para a preparação de um ácido bifenil-2-il carbâmico BR112013000877B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36372510P 2010-07-13 2010-07-13
US61/363,725 2010-07-13
PCT/US2011/042530 WO2012009166A1 (en) 2010-07-13 2011-06-30 Process for preparing a biphenyl-2-ylcarbamic acid

Publications (2)

Publication Number Publication Date
BR112013000877A2 true BR112013000877A2 (pt) 2016-05-17
BR112013000877B1 BR112013000877B1 (pt) 2021-07-06

Family

ID=44514976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000877-6A BR112013000877B1 (pt) 2010-07-13 2011-06-30 processo para a preparação de um ácido bifenil-2-il carbâmico

Country Status (22)

Country Link
US (2) US8754225B2 (pt)
EP (1) EP2593429B1 (pt)
JP (2) JP5959117B2 (pt)
KR (1) KR101742253B1 (pt)
CN (1) CN102958916B (pt)
AU (1) AU2011279602B2 (pt)
BR (1) BR112013000877B1 (pt)
CA (1) CA2801101C (pt)
DK (1) DK2593429T3 (pt)
ES (1) ES2544287T3 (pt)
HK (1) HK1184145A1 (pt)
HR (1) HRP20150700T1 (pt)
HU (1) HUE027140T2 (pt)
IL (1) IL223328A (pt)
MX (1) MX2013000456A (pt)
PL (1) PL2593429T3 (pt)
PT (1) PT2593429E (pt)
RS (1) RS54201B1 (pt)
SG (1) SG186708A1 (pt)
SI (1) SI2593429T1 (pt)
SM (1) SMT201500204B (pt)
WO (1) WO2012009166A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
AU2010273514B2 (en) 2009-07-15 2015-01-22 Theravance Biopharma R&D Ip, Llc Crystalline freebase forms of a biphenyl compound
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
CN110526859B (zh) * 2019-08-07 2021-03-12 山东百诺医药股份有限公司 一种瑞维那新中间体及其制备方法和瑞维那新的制备方法
WO2022049604A1 (en) * 2020-09-05 2022-03-10 Cipla Limited Process for preparing revefenacin and intermediates therof
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
CN113121412A (zh) * 2021-04-20 2021-07-16 扬州中宝药业股份有限公司 一种雷芬那辛中间体的制备方法
WO2023002502A1 (en) * 2021-07-17 2023-01-26 Msn Laboratories Private Ltd, R&D Center Novel process for the preparation of 1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]- n-methylbenzamido}ethyl)piperidin-4-yl n-({1,1'-biphenyl}-2-yl)carbamate
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin
CN114276290B (zh) * 2021-12-24 2024-05-28 浙江和泽医药科技股份有限公司 一种雷芬那辛无水晶型及其制备方法
CN115093365B (zh) * 2022-07-25 2023-07-25 沈阳药科大学 一种雷芬那辛的合成方法
CN116514704B (zh) * 2023-07-01 2023-09-29 北京远大九和药业有限公司 一种雷芬那辛中间体及其制备方法
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6816878B1 (en) * 2000-02-11 2004-11-09 Steven L. Zimmers Alert notification system
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7228657B2 (en) 2003-07-10 2007-06-12 Controlled Environments Limited Climate control for a greenhouse
US7345060B2 (en) * 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
AU2010273514B2 (en) * 2009-07-15 2015-01-22 Theravance Biopharma R&D Ip, Llc Crystalline freebase forms of a biphenyl compound

Also Published As

Publication number Publication date
HRP20150700T1 (hr) 2015-08-14
IL223328A (en) 2015-07-30
KR101742253B1 (ko) 2017-05-31
BR112013000877B1 (pt) 2021-07-06
PT2593429E (pt) 2015-09-24
AU2011279602B2 (en) 2015-04-09
HK1184145A1 (en) 2014-01-17
IL223328A0 (en) 2013-02-03
JP2015127342A (ja) 2015-07-09
AU2011279602A1 (en) 2013-02-21
JP2013532631A (ja) 2013-08-19
US9035061B2 (en) 2015-05-19
PL2593429T3 (pl) 2015-10-30
CA2801101A1 (en) 2012-01-19
MX2013000456A (es) 2013-02-27
EP2593429B1 (en) 2015-06-03
SMT201500204B (it) 2015-10-30
EP2593429A1 (en) 2013-05-22
SG186708A1 (en) 2013-02-28
US20140121378A1 (en) 2014-05-01
HUE027140T2 (hu) 2016-08-29
US20120016130A1 (en) 2012-01-19
CN102958916B (zh) 2015-03-25
WO2012009166A1 (en) 2012-01-19
JP5959117B2 (ja) 2016-08-02
US8754225B2 (en) 2014-06-17
DK2593429T3 (en) 2015-09-07
CA2801101C (en) 2018-01-16
CN102958916A (zh) 2013-03-06
SI2593429T1 (sl) 2015-10-30
KR20130129177A (ko) 2013-11-27
ES2544287T3 (es) 2015-08-28
RS54201B1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
BR112013000877A2 (pt) processo para a preparação de um ácido bifenil-2-il carbâmico
BR112012028395A2 (pt) processo para preparar ditiina-tetracarboxi-diimidas
BRPI0919192A2 (pt) Uso de lipídio, composição nutricional, e, processo para a produção de uma composição nutricional
BR112015010306A2 (pt) modificadores de impacto novo para adesivos à base de epóxi
BRPI0916712A2 (pt) processo para preparar uma composição detergente
BRPI0821290A2 (pt) Moldagem produzível por um processo, processo para produzir uma moldagem, painel, e, uso de uma moldagem
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
BRPI0806556A2 (pt) Processo para produzir um isocianato
BR112013002925A2 (pt) processo para a síntese de ácido 2,5-furandicarboxílico
BRPI0922984A2 (pt) processo para preparar trietanolamina pura
BRPI0914042A2 (pt) processo para a produção de uma ou mais etilenoaminas por uma reação de transaminação
MX2012000682A (es) Formas de bases libres cristalinas de un compuesto de bifenilo.
BRPI0921399A2 (pt) composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante
BRPI0909280A2 (pt) processo para preparar uretanos.
BR112014006454A2 (pt) composição degeladora , e, processo para produzir uma composição degeladora
BR112012001349A2 (pt) processo livre de solvente para a produção de uma composição adesiva, e, composição adesiva livre de cargas
BR112013012873A2 (pt) processo para preparar uma n, n-dialquiletanolamina
BRPI0916512A2 (pt) processo para produzir uma composição agroquímica de partícula dispersível em água
BR112012028644A2 (pt) processo para separação de ácido acrílico de uma composição
BRPI0917836A2 (pt) processo para preparar uretanos
BRPI1008987A2 (pt) processo para preparar 3,3,3-trifluoropropeno
BR112012024852A2 (pt) composição curável e processo para preparar uma composição curável
BR112013015874A2 (pt) processo para a separação de uma mistura.
BR112013005986A2 (pt) processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo
BR112012026157A2 (pt) processo para preparar ditiina-tetracarboximidas.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 211/46

Ipc: C07D 211/46 (2006.01), A61P 11/00 (2006.01), C07D

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.